• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.加拿大直接作用抗病毒药物（DAA）的公共支付与私人支付比较。
Can Liver J. 2021 Nov 11;4(4):426-429. doi: 10.3138/canlivj-2020-0041. eCollection 2021 Fall.
2
Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.加拿大艾滋病毒与丙型肝炎合并感染人群中直接作用抗病毒药物使用情况的差异。
J Int AIDS Soc. 2017 Nov;20(3). doi: 10.1002/jia2.25013.
3
Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.德国慢性丙型肝炎感染的真实世界治疗：2010-2015 年药物处方数据分析。
J Hepatol. 2017 Jul;67(1):15-22. doi: 10.1016/j.jhep.2017.01.024. Epub 2017 Feb 9.
4
Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET Medical Information Database Network in Japan.利用日本 MID-NET 医学信息数据库网络评估接受直接作用抗病毒药物治疗丙型肝炎患者肾功能下降的风险。
Ther Innov Regul Sci. 2022 Jul;56(4):625-631. doi: 10.1007/s43441-022-00400-5. Epub 2022 Apr 18.
5
Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.迈向加拿大丙型肝炎感染直接作用抗病毒治疗的全民覆盖：对加拿大各省和国际司法管辖区的环境扫描。
J Pharm Pharm Sci. 2018;21(1s):271s-308s. doi: 10.18433/jpps30220.
6
Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment.制药公司向日本丙型肝炎治疗临床实践指南作者支付的款项。
Liver Int. 2021 Mar;41(3):464-469. doi: 10.1111/liv.14761. Epub 2020 Dec 23.
7
Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan.巴基斯坦旁遮普省聚乙二醇干扰素和直接作用抗病毒药物治疗后丙型肝炎病毒的复发。
Braz J Biol. 2021 Dec 13;83:e252610. doi: 10.1590/1519-6984.252610. eCollection 2021.
8
A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.台湾地区直接作用抗病毒药物和干扰素治疗丙型肝炎的药物利用和临床结局的真实世界观察性研究。
Curr Med Res Opin. 2021 Feb;37(2):245-252. doi: 10.1080/03007995.2020.1857716. Epub 2021 Jan 13.
9
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.丙型肝炎治疗差异从干扰素时代到直接抗病毒药物时代的转变：一项基于人群的队列研究。
J Viral Hepat. 2017 Aug;24(8):624-630. doi: 10.1111/jvh.12684. Epub 2017 Feb 20.
10
Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.荷兰 HIV/丙型肝炎病毒合并感染患者中直接作用抗病毒药物药物相互作用的管理：足够但不完美。
HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1.

引用本文的文献

1
Universal Pharmacare and Contraceptive Dispensations Among Youth.青少年中的全民医保与避孕药具发放
JAMA Pediatr. 2025 Aug 18. doi: 10.1001/jamapediatrics.2025.2585.
2
Health service utilization, substance use treatment response, and death in patients with opioid use disorder and comorbid hepatitis C findings from prospective cohort study with administrative database linkage.在一项前瞻性队列研究中，通过与行政数据库的链接，研究了患有阿片类药物使用障碍和合并丙型肝炎的患者的卫生服务利用、物质使用治疗反应和死亡情况。
J Subst Use Addict Treat. 2024 Dec;167:209524. doi: 10.1016/j.josat.2024.209524. Epub 2024 Sep 26.
3
The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.加拿大扩大直接作用抗病毒药物获取途径对丙型肝炎病毒患者结局的影响。
PLoS One. 2023 Aug 8;18(8):e0284914. doi: 10.1371/journal.pone.0284914. eCollection 2023.
4
Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.加拿大丙型肝炎病毒感染直接抗病毒治疗的公共报销政策：一项描述性研究。
Can Liver J. 2023 Jul 26;6(2):190-200. doi: 10.3138/canlivj-2022-0040. eCollection 2023 Jul.
5
Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.在丙型肝炎病毒感染者中使用直接作用抗病毒药物：一项定性研究。
Int J Equity Health. 2023 Jun 6;22(1):112. doi: 10.1186/s12939-023-01924-4.
6
Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study.安大略省丙型肝炎直接抗病毒治疗可及性的地区差异：一项横断面研究。
Can Commun Dis Rep. 2022 Apr 6;48(4):179-180. doi: 10.14745/ccdr.v48i04a08.

本文引用的文献

1
Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018.2014 年至 2018 年美国和加拿大丙型肝炎抗病毒药物的支出。
Value Health. 2020 Sep;23(9):1137-1141. doi: 10.1016/j.jval.2020.03.021. Epub 2020 Jul 28.
2
Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.加拿大强制性非医学转换生物制剂治疗风湿性疾病和炎症性肠病的潜在成本影响。
Clin Pharmacol Ther. 2021 Mar;109(3):739-745. doi: 10.1002/cpt.2042. Epub 2020 Oct 3.
3
National trends in prescription drug expenditures and projections for 2020.全国处方药支出趋势及 2020 年预测。
Am J Health Syst Pharm. 2020 Jul 23;77(15):1213-1230. doi: 10.1093/ajhp/zxaa116.
4
Direct-acting antiviral treatment for hepatitis C.丙型肝炎的直接抗病毒治疗
Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11.
5
Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015.2010 至 2015 年加拿大胰岛素使用和支出趋势分析。
Can J Diabetes. 2019 Apr;43(3):179-185.e1. doi: 10.1016/j.jcjd.2018.08.190. Epub 2018 Aug 16.
6
Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.加拿大的处方药保险范围：对全民药物保险的经济、政策和政治考量的综述
J Pharm Policy Pract. 2018 Nov 7;11:28. doi: 10.1186/s40545-018-0154-x. eCollection 2018.
7
Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.迈向加拿大丙型肝炎感染直接作用抗病毒治疗的全民覆盖：对加拿大各省和国际司法管辖区的环境扫描。
J Pharm Pharm Sci. 2018;21(1s):271s-308s. doi: 10.18433/jpps30220.
8
Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults.加拿大老年人精神药物处方的省际差异。
Can Geriatr J. 2018 Sep 30;21(3):269-273. doi: 10.5770/cgj.21.307. eCollection 2018 Sep.
9
Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.2011年加拿大丙型肝炎病毒感染的估计患病率。
Can Commun Dis Rep. 2014 Dec 18;40(19):429-436. doi: 10.14745/ccdr.v40i19a02.
10
Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.灾难性药物保险：安大略省延龄草药物计划的使用见解
CMAJ Open. 2018 Mar 14;6(1):E132-E138. doi: 10.9778/cmajo.20170132.

Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.

作者信息

Shakeri Ahmad, Hayes Kaleen N, Gomes Tara, Tadrous Mina

机构信息

Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.

Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

出版信息

Can Liver J. 2021 Nov 11;4(4):426-429. doi: 10.3138/canlivj-2020-0041. eCollection 2021 Fall.

DOI:10.3138/canlivj-2020-0041
PMID:35989895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9235118/
Abstract
摘要